Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZL-1211 · 1 trial · 1 indication
To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of ZL-1211
Incidence of Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Objective response rate defined as the proportion of patients with partial response (PR) proportion of patients with partial response (PR) or complete response (CR) based on Investigator assessment of tumor lesions per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
| Arm | Type | Description |
|---|---|---|
| ZL-1211 monotherapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ZL-1211 | DRUG | Phase 1 dose escalation part will enroll about 12-42 patients, Phase 2 dose expansion part will enroll about 15-40 patients in each cohort |
Inclusion Criteria: Patients are eligible to be included in the study only if all the following inclusion criteria apply: 1. Adults≥ 18 years of age. 2. Willing and able to provide signed and dated informed consent prior to any study related procedures and willing and able to comply with all study...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ZL-1211 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has been studied in patients with advanced solid tumors. The drug is not yet approved and remains under investigation.
ZL-1211 is being developed by Zai Lab Limited, a biopharmaceutical company traded on the NASDAQ under the ticker ZLAB. The company is conducting clinical research on this investigational oncology drug for advanced solid tumors.
ZL-1211 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 study has been completed, and the drug remains in early-stage clinical investigation for advanced solid tumors.
ZL-1211 has been studied in a Phase 1 clinical trial with the identifier NCT05065710, titled "A Study of ZL-1211 in Patients With Advanced Solid Tumor." This single-arm, uncontrolled study enrolled 34 patients with advanced solid tumors and was conducted in the United States and China.
ZL-1211 is the primary name for this investigational drug. No alternative names have been established for this compound in the available clinical trial information. It is identified solely as ZL-1211 in the registered study.